Report an error   
Advanced Search

Role of Rosuvastatin pretreatment in preventing Contrast Induced Nephropathy in patients undergoing Percutaneous Coronary Intervention.


Aira B. Beringuel

Related Institution

Department of Internal Medicine - Cardinal Santos Medical Center

Publication Information

Publication Type
Book of Abstracts
Publication Sub Type
CSMC Research Abstract Compendium


BACKGROUND: Several studies have suggested that statin pretreatment prevents contrast- induced nephropathy (CIN) in patients who have undergone percutaneous intervention. This meta-analysis aims to study the effect of rosuvastatin in prevention of such in patients with or without chronic kidney disease.  

METHODOLOGY: We searched PUBMED for studies regarding rosuvastatin and its role for preventing CIN in patients with or without known renal disease. Our main outcome is to evaluate the effect if pretreatment with rosuvastatin has effect in reducing the incidence if CIN.  

RESULTS: Two studies with a total of 4272 patients were identified and analyzed. The overall results based on fixed-effect model showed that the use of rosuvastatin treatment was associated with a significant reduction in risk of CIN (OR = 0.56, 95% CI 0.42-0.74, p = <0.00001; I2 = 53%).  

CONCLUSION:  Although this meta-analysis supports the use of rosuvastatin to reduce the incidence of CIN, it still depends on patient's demographics. 

Physical Location

LocationLocation CodeAvailable FormatAvailability
Cardinal Santos Medical Center - Research Center Abstract Print Format

©2022 HERDIN PLUS. All rights reserved. | Contact Us | Keep up to date